Hunter Perkins Capital Trims Johnson & Johnson Holdings

The investment firm reduced its stake in the pharmaceutical giant by over 40% in Q4 2025.

Mar. 31, 2026 at 9:21am

Got story updates? Submit your updates here. ›

A high-contrast, macro-level view of the gears, pipes, and mechanical components that comprise the manufacturing infrastructure of a major pharmaceutical company, conveying the industrial scale and technical complexity of the modern drug industry.The complex inner workings of a pharmaceutical giant like Johnson & Johnson reflect the scale and sophistication of the modern drug industry.New Brunswick Today

Hunter Perkins Capital Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 41.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 31,489 shares of the company's stock after selling 22,056 shares.

Why it matters

Johnson & Johnson is one of the world's largest and most influential pharmaceutical companies, so changes in major institutional investors' holdings can signal broader trends in the industry and economy.

The details

Hunter Perkins Capital Management, an investment firm based in New Jersey, reduced its stake in Johnson & Johnson by over 40% in the fourth quarter of 2025. The firm previously held 53,545 shares of the company but sold 22,056 shares, leaving it with a position of 31,489 shares worth approximately $6.52 million.

  • Hunter Perkins Capital Management filed its Q4 2025 disclosure with the SEC on March 31, 2026.

The players

Hunter Perkins Capital Management LLC

A New Jersey-based investment management firm that oversees a portfolio of stocks, bonds, and other assets.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

The takeaway

This reduction in a major institutional investor's Johnson & Johnson holdings could signal broader caution or shifting priorities in the pharmaceutical sector, though the firm still maintains a sizable position in the blue-chip stock.